Laboratory of Regenerative Pharmacology, Goldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, Tomsk, Russia.
Stem Cell Biology and Regenerative Medicine Group, School of Pharmacy, University of Reading, Whiteknights Campus, Reading, RG6 6AP, UK.
Int J Chron Obstruct Pulmon Dis. 2021 Dec 30;16:3575-3591. doi: 10.2147/COPD.S336410. eCollection 2021.
Endothelial dysfunction and destruction of the pulmonary microcirculation are important pathogenic factors in chronic obstructive pulmonary disease (COPD). In COPD, bronchial obstruction is associated with endothelial dysfunction. Thus, new pharmacological treatment options aimed at restoring the pulmonary endothelium represent a clinical need in COPD therapy. Notch1 has been shown to protect cells against apoptosis, inflammation, and oxidative stress caused by cigarette smoke extract (CSE). Therefore, drug which effect on Notch1 may be a potential therapeutic target for COPD in the future.
In this study, we assessed the potential of spiperone to mediate regeneration of pulmonary endothelium in model of pulmonary emphysema induced by a CSE and lipopolysaccharide (LPS) in female C57BL/6 mice.
Spiperone increased the number of capillaries as well as the expression of the CD31 in the alveolar tissue compared to the controls. Moreover, application of spiperone prevented alveolar wall destruction (DI), and reduced the area of emphysema. Lastly, we demonstrated that spiperone positively influenced mobilization and migration of endothelial progenitor cells (EPC, CD45CD34CD31), CD309-endothelial cells, and angiogenesis precursors (CD45CD117CD309) into the lung. Spiperone administration significantly reduced the number Notch1 positive CD309-endothelial cells and Notch1+ EPCs.
Overall, our results suggest that spiperone mediates endothelial regeneration in an animal model of COPD. Thus, it could represent a novel therapeutic approach for treatment of emphysema associated with COPD.
内皮功能障碍和肺微循环破坏是慢性阻塞性肺疾病(COPD)的重要发病因素。在 COPD 中,支气管阻塞与内皮功能障碍有关。因此,旨在恢复肺内皮的新的药理学治疗选择代表了 COPD 治疗中的临床需求。 Notch1 已被证明可保护细胞免受香烟烟雾提取物(CSE)引起的细胞凋亡、炎症和氧化应激的影响。因此,作用于 Notch1 的药物可能是 COPD 未来的潜在治疗靶点。
在这项研究中,我们评估了 spiperone 在 CSE 和脂多糖(LPS)诱导的女性 C57BL/6 小鼠肺气肿模型中介导肺内皮再生的潜力。
与对照组相比,spiperone 增加了毛细血管的数量以及肺泡组织中 CD31 的表达。此外,spiperone 的应用可防止肺泡壁破坏(DI),并减少肺气肿面积。最后,我们证明 spiperone 可积极影响内皮祖细胞(EPC,CD45CD34CD31)、CD309-内皮细胞和血管生成前体(CD45CD117CD309)向肺的动员和迁移。 spiperone 给药显著减少了 Notch1 阳性 CD309-内皮细胞和 Notch1+EPC 的数量。
总体而言,我们的结果表明 spiperone 在 COPD 动物模型中介导内皮再生。因此,它可能代表治疗与 COPD 相关的肺气肿的一种新的治疗方法。